Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120 by Takeda, Akira et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
1992-06-01 
Distinction of human immunodeficiency virus type 1 
neutralization and infection enhancement by human monoclonal 
antibodies to glycoprotein 120 
Akira Takeda 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Immunology and Infectious Disease Commons 
Repository Citation 
Takeda A, Robinson JE, Ho DD, Debouck C, Haigwood NL, Ennis FA. (1992). Distinction of human 
immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal 
antibodies to glycoprotein 120. Open Access Articles. https://doi.org/10.1172/JCI115802. Retrieved from 
https://escholarship.umassmed.edu/oapubs/1006 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Distinction of Human Immunodeficiency Virus Type 1 Neutralization and Infection
Enhancement by Human Monoclonal Antibodies to Glycoprotein 120
Akira Takeda,* James E. Robinson, David D. Ho, Chrisfine Debouck, Nancy L. Haigwood, and Francis A. Ennis*
*Division ofInfectious Diseases, Department ofMedicine, University ofMassachusetts Medical School, Worcester, Massachusetts 01655;
Department ofPediatrics and Microbiology, Immunology and Parasitology, Louisiana State University School ofMedicine, New
Orleans, Louisiana 70112; Division ofInfectious Diseases, The Aaron DiamondAIDS Research Center, New York University School of
Medicine, New York 10016; Department ofMolecular Genetics, Smith Kline Beecham Pharmaceuticals, King ofPrussia, Pennsylvania
19479; and Chiron Corporation, Emeryville, California 94608
Abstract
There is increasing evidence that sera from HIV-1-infected
individuals contain antibodies that enhance infection by HIV-1
in vitro. Previous work has demonstrated that complement re-
ceptors on T lymphoid cells and Fc receptors for IgG (Fc'yR) on
monocytic cells are required for enhanced infection by anti-
body-complexed HIV-1. Characterization of such infection-en-
hancing antibodies is essential because immunogenic epitopes
which induce enhancing antibodies should be excluded from
HIV-1 vaccines. This study was conducted to identify enhanc-
ing antibodies involved in Fc R-mediated enhancement ofHIV-
1 infection employing IgG human monoclonal antibodies
(HMAbs) reactive against gpl20 of HIV-1, which were pro-
duced by B cell lines derived from an HIV-1-infected individ-
ual. A potent neutralizing HMAb N70-1.5e did not enhance
infection by HIV-1 (IIIB and MN strains), whereas HMAb
N70-2.3a mediated enhancement of HIV-1 infection, but had
little neutralizing activity. A competition radio immunoassay
demonstrated that the two antibodies bind to distinct epitopes.
These results indicated that enhancing and neutralizing antibod-
ies can be induced by different epitopes on gpl20, suggesting
the potential for development of safe vaccines against HIV-1 by
exclusion of immunogenic epitopes for enhancing antibodies.
We made attempts to identify the epitope on gpl20 that is
recognized by the enhancing antibody N70-23a by using recom-
binant HIV-1 proteins and found that the antibody binds to a
conformational site of nonvariable sequences in the carboxyl
half (aa 272-509) of gpl20. (J. Clin. Invest. 1992. 89:1952-
1957.) Key words: HIV-1 * infection enhancement * neutraliza-
tion * monoclonal antibodies * epitope
Introduction
Enhancement of HIV-1 infection by specific antibodies has
been described in vitro (1-6). This raises a major concern in
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1. Abbreviations used in this paper: FBS, fetal bovine serum; FcR, Fc
receptor; HMAb, human monoclonal antibodies; HTLV, human T
cell lymphotrophic virus.
reference to HIV vaccine development, since very low concen-
trations of anti-HIV- 1 antibodies can enhance HIV- 1 infec-
tion. Robinson et al. first reported complement-mediated en-
hancement of HIV- 1 infection in a T cell line bearing comple-
ment receptors (1). We have previously demonstrated
antibody-dependent enhancement of HIV-l infection via Fc
receptor (FcR)'-mediated entry using a human monocytic cell
line U937 that possesses FcRs for IgG (3). Heat-inactivated
sera from HIV- 1 antibody-positive individuals enhanced infec-
tion ofU937 cells. This enhancement was blocked by the pres-
ence of heat-aggregated -globulin, a potent ligand for FcRs.
The IgG fraction from an HIV- 1 antibody-positive serum-en-
hanced HIV-1 infection at the same serum dilution equiva-
lents. IgG-F(ab')2 failed to enhance HIV-1 infection, but still
possessed neutralizing activity for HIV-1. We thus concluded
that the enhancement of HIV- 1 infection requires the Fc por-
tion of IgG and is mediated by Fc Rs. We examined several
HIV-1 antibody positive sera, and enhancement of infection
was generally detected at higher dilutions of the sera. The en-
hancement at subneutralizing concentrations raised a ques-
tion: are enhancing antibodies and neutralizing antibodies dif-
ferent categories ofantibodies, or are these activities concentra-
tion-dependent phenomena due to the same antibodies? To
address this question, we examined the reactivity ofthe sera on
Western blots to antigens of HIV- I (human T cell lymphotro-
phic virus-IIIB strain [HTLV-IIIB]) to determine whether en-
hancing sera react with specific viral antigens; however, there
were no specific differences in terms of major viral proteins
between enhancing sera and nonenhancing sera (data not
shown).
Therefore, we have attempted to approach this issue by
using rabbit antisera raised against the amino- and the car-
boxyl-terminal halves of HIV-l gpl20, and human monoclo-
nal antibodies (HMAbs) directed against gpl2O, which were
derived from HIV- 1-infected donor peripheral blood lympho-
cytes.
Methods
Viruses. HTLV-IIIB, a prototype HIV-1 strain (7) and HTLV-IIIMN
(7) were obtained from the AIDS Research and Reference Reagent
Program. These strains were grown in H9 cells as acutely infected cul-
tures. A local strain, HIV- I J62 (8), that was isolated from the periph-
eral blood mononuclear cells ofan HIV-l-infected patient by coculti-
vation with mitogen-stimulated T cells from seronegative blood, was
used to prepare native gp 120 antigen for binding assays.
Rabbit antisera raised against recombinant HIV-1 envelope con-
structs. Recombinant protein Kp12ONN corresponding to the amino-
terminal moiety ofgpl20 (aa 12-257) was obtained by expression of a
738-bp Asp718I-PvuII filled-in restriction gpl2O gene fiagment in-
serted in the pOTSKF33 bacterial vector (9). Recombinant protein
Kpl20C corresponding to the carboxyl-terminal halfofgpl20 (aa 258-
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437) was obtained by expression of a 539-bp PvuII-HindIII filled-in
restriction fragment, in which an oligonucleotide containing transla-
tion stop codons in all three frames was inserted at the BglII site at the
end ofgpl20. The gene fragments were isolated from the BHI 0 clone of
HIV-l (10). Polyclonal antibodies were obtained from rabbits that were
hyperimmunized with those constructs. The reactivity of those rabbit
sera with each construct was tested by ELISA.
Human monoclonal antibodies to HIV-J gpJ20. IgG HMAbs with
specificity for HIV-l gpl20 were produced by EBV-transformed B cells
established from peripheral blood of asymptomatic HIV-l-infected
subjects, as described previously (11). We used two HMAbs, designated
N70-l .5e and N70-2.3a, that are derived from the same donor and bind
to HTLV-IIIB. N70-l.5e identifies a relatively conserved conforma-
tional epitope on gpl20 that is glycosylation dependent, and is in-
volved in binding ofgpl20 to CD4. This antibody has potent neutraliz-
ing activity against a variety oflaboratory and primary strains ofHIV- 1
(12). N70-2.3a reacts with a well-conserved epitope on gpl2O, and its
poor reactivity with reduced gp 120 suggested it recognized a conforma-
tion-dependent epitope (11). Both are of the IgGl subclass and are
directed against relatively conserved epitopes of gpl20. N70-2.3a has
reacted with all 12 strains tested, including HTLV-IIIB and HTLV-
IIIRF, and N70-l.5e reacts with a majority of strains but not with RF.
Another HMAb, N70-1.9b, which recognizes a linear epitope within
the V3 region ofMN and J62, and does not bind to virus strains that
lack the V3 region ofMN (13), was also 13 used for binding assays to
determine relative affinities of N70-l.5e and N70-2.3a.
HIV-I infection enhancement assay in U937 cells. The assay for the
detection of enhancement of HIV-l infection was performed with
HTLV-IIIB, using a slightly modified method from that which we
described previously (3). Cell-free HIV-l (HTLV-IIIB strain) har-
vested from an acutely infected H9 culture and titrated on C8166 cells
was used as the virus inoculum. In a part of the experiments we also
used an HIV-l strain HTLV-IIIMN. Briefly, an HIV-l inoculum (0.1
ml) containing 5 x 103 50% tissue culture infective dose (TCID50) in
RPMI 1640 medium supplemented with 2% fetal bovine serum (FBS)
(GIBCO Laboratories, Grand Island, NY) was mixed with a 0.9-ml
portion of heat-inactivated (56°C for 30 min) rabbit antiserum, or a
monoclonal antibody that was serially diluted tenfold from 10-' to
l0-7 in RPMI 1640 medium, and then incubated for 30 min at 4°C.
These virus-antibody mixtures were then incubated for 1 h at 37°C
with 5 x I0O U937 cells (American Type Tissue Collection, Rockville,
MD). The infected U937 cells were washed three times and resus-
pended at 2 x I05 cells/ml in RPMI 1640 medium supplemented with
10% FBS, 10 mM Hepes buffer, 2 mM L-glutamine, 100 U/ml ofpeni-
cillin, and 100I g/ml ofstreptomycin. Each ofthe l-ml cell suspensions
was then cultured in 48-well multiculture plates (Costar Data Packag-
ing, Cambridge, MA). On day 3, half of the culture medium in each
well was replaced with fresh medium. On day 5, the culture superna-
tants were harvested for determination of virus yields by p24 ELISA
(DuPont Instruments, Wilmington, DE) (14). Each experiment was
performed with duplicate cultures. Previously, we demonstrated that
the enhanced infection measured by yields ofp24 was confirmed by the
percent cytoplasmic HIV-l antigen-positive cells detected by an indi-
rect immunofluorescence assay (3).
HIV-J neutralization assay in H9 cells. Neutralization assays were
performed against HTLV-IIIB, as described previously (15). Each virus
inoculum (100 ul, 50 TCID50) was preincubated with indicated
amounts ofantibodies at serial dilutions (100,ul) for 1 h at 37°C before
inoculation onto 2 X 106 H9 cells in 5 ml of RPMI 1640 medium
supplemented with 20% FBS. On days 7- 10, each ofthe culture super-
natants was examined for p24 antigen. Neutralization was defined as
> 90% reduction in supernatant p24 antigen, compared with control
cultures.
Competition radioimmunoassay. Purified HIV-1 glycoproteins
from the J62 strain were immobilized on small strips of nitrocellulose
and blocked in BSA (11). 90 Mg of purified HMAb N70-2.3a was ra-
dioiodinated by Iodobeads (BioRad Laboratories, Richmond, CA),
(lactoperoxidase) method. The radioactivity ofthe labeled HMAb was
- 115,000 cpm/Mg. Immobilized antigen or control nitrocellulose
strips were incubated with 50 ug/ml of purified HMAb, N70-l.5e,
N70-2.3a, or buffer for 1 h, and then washed. Labeled HMAb N70-2.3a
was added for 1 h and then the nitrocellulose strips were washed and
counted for radioactivity.
Recombinant HIV-I gpJ20 proteins. Nonglycosylated HIV-SF2 re-
combinant envelope polypeptides, designated as env-2-3 (full length
protein, AA2b-5 10), env 1 (NH2-terminal half, AA2b-376), env 4
(COOH-terminal half, AA272-509), and variants deleted in one to five
hypervariable regions, were obtained by expression ofgp 120 gene frag-
ments inserted into the pHL15 yeast vector, as described previously
(16). The gene fragments were derived from HIV-SF2 strains (17).
ELISA with envelope polypeptides. Recombinant gp120 proteins
were absorbed to microtiter plates at 2 ug/ml in borate buffer. After
plates were washed, biotinylatedHMAb N70-2.3a that was diluted seri-
ally was added for 1 h and detected using streptavidin, streptavidin
conjugated to horseradish peroxidase (HRP-streptavidin; Zymed Labs,
Inc., San Francisco, CA). Wells were developed with 2,2'-amino-bis
(3-ethyl-benzenethiozyline 6-sulfonic acid) (ABTS) (Sigma Chemical
Co., St. Louis, MO).
Comparison ofHMab binding affinities. To compare the relative
affinities of 1.5e and 2.3a, we used an assay based in principle on the
method of Friguet et al. (18), in which antibody is first incubated in
solution with antigen and then the relative amount of unbound anti-
body is determined by indirect ELISA. For these experiments, both
HMAbs were biotinylated as previously described (12), and used at an
estimated final concentration of 8 ng/ml. In the solution phase reac-
tion, biotinylated antibodies were mixed with equal volumes ofbaculo-
virus expressed recombinant gpl20 at final concentrations ranging
from 0.25 to 4 ug/ml. Controls consisted of biotinylated antibodies
mixed with dilution buffer alone. After 2 h at room temperature, the
antibody-antigen mixtures were incubated with solid-phase gpl20 and
the amount ofunbound biotin-HMab was measured by ELISA, using
peroxidase-conjugated streptavidin as the detecting reagent and TMB-
H202 as chromogenic substrate.
In the ELISA, solid-phase antigen consisted of native gp 120 from
the HIV-1I62 strain captured in 96-well Immulon II assay plates (Dyna-
tech Laboratories, Chantilly, VA) coated for 1 h with 5 Mg/ml ofHMAb
N70-1.9b. This antibody identifies a highly strain-restricted epitope
within the V3 loop ofstrains J62 and HTLV-IIIm. (13), and it does not
compete with either 2.3a or l.5e. N70-1.9b was used as a capture re-
agent since it does not react with LAV gpl20 (11), and hence, could not
generate false signals by binding to soluble phase LAV gpl 20-HMAb
complexes. The source of native J62 gp 120 was detergent-treated cell-
free culture fluid from a chronically infected continuous T cell line. We
also established in earlier studies that 2.3a and l.5e showed equivalent
reactivity with both LAV rgpl20 and native J62 gpl20 in an ELISA in
which gpl20 was immobilized in Con A-coated wells (8).
Statistics. Data from infection enhancement assays were analyzed
using quadratic assumption because the data fit a quadratic model with
a P value less than 0.05. When the model was not significant, the analy-
sis of variance with a Student-Newman-Keuls t test was used.
Results
Localization ofenhancing epitopes using rabbit antisera. Initial
experiments were conducted to define whether the major gly-
coprotein gpl20 has functional site(s) that can elicit enhancing
antibodies. It is known that this envelope protein contains ma-
jor epitopes recognized by the humoral immune system. We
tested heat-inactivated polyclonal rabbit antisera raised against
recombinant proteins corresponding to the amino-terminal
half or the carboxyl-terminal half of gpl2O for infection-en-
hancing activity, and found that both of these polyclonal anti-
sera showed inhibitory activity at high concentrations of sera,
and enhanced infection at lower sera concentrations (Table I).
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Table I. HIV-J Infection Enhancement Activity in Polyclonal
Rabbit Antisera Raised Against Recombinant
HIV-J Envelope Contructs
Serum dilution p24 (ng/ml)t
Control Rabbit antisera* Directed against
rabbit
serum* Kpl20 C Kpl20 NN
HIV alone 30.75±2.75 31.0±2.0 (1.0) 30.75±1.75 (1.0)
10-' 11.75±1.25 <1.0 5.75±2.75
10-2 12.5±1.5 5.25±1.75 14.25±3.25
10-3 15.0±0.5 21.0±0.5 26.5±8.0
0-4 29.75±1.25 38.0±4.5 36.0±0.5
l-, 26.5±1.5 43.75±6.25 (1.41) 48.75±7.25 (1.59)
10-6 32.75±1.25 44.0±2.0 (1.42) 33.75±2.25
1o-7 29.5±2.5 36.0±2.5 29.0±5.0
* All rabbit sera were heat inactivated (560C for 30 min) before being
tested. $ The results of one of two similar experiments are shown.
P24 values are expressed as the mean±SD of duplicate cultures. The
numbers in parentheses represent the enhancement indices compared
with the control of HIV-1 alone.
Thus gp 120 appears to contain epitopes that induce enhancing
as well as neutralizing antibodies in both its amino- and car-
boxyl-terminal moieties, although it remains uncertain
whether those epitopes are identical or distinct.
Neutralizing and enhancing activities ofHMAbs. Thus, to
explore the possibility that enhancing and neutralizing antibod-
ies may be induced by distinct epitopes, we used HMAbs to
gpl 20, which were recently described (1 1). We used HMAbs
N70-1.5e and N70-2.3a; both are of the IgGI subclass and are
directed against conserved epitopes on gpl20. We tested for
neutralizing activity of HTLV-IIIB infection of H9 cells, as
shown in Fig. 1, a and b. N70-2.3a exhibits weak, equivocal
neutralizing activity against HTLV-IIIB in HIV-l neutraliza-
tion assays (15); neutralizing activity as defined as more than
90% inhibition was only observed at antibody concentrations
of 10 tg/ml. The otherHMAb N70- 1 .5e showed potent neutral-
a N70-2.3aNb N701 use
Antibody (pig) Antibody (pig)
Figure 1. HIV-I-neutralizing activities of human monoclonal anti-
bodies N70-2.3a (a) and N70-1.5e (b). Neutralization assays were
performed against HTLV-IIIB, as described in Methods. Indicated
amounts of antibodies (100 Ml) were preincubated with virus inocu-
lum (100 ul, 50 TCID50) for 1 h at 370C and then mixed with 2 X 106
H9 cells. On days 7 through 10, each ofthe culture supernatants was
examined for p24 antigen. Neutralization was defined as > 90% re-
duction in supernatant p24 antigen compared with control cultures.
izing activity against HTLV IIIB, even at antibody concentra-
tions as low as 1 gg/ml.
On the other hand, assays for enhancement of infection
showed reciprocal results (Fig. 2, a and b). Infection enhance-
ment assays were performed using a slightly modified method
from that which we described previously (3). Enhancement of
HIV-l infection was observed with N70-2.3a, which enhanced
HTLV IIIB infection at HMAb dilutions ranging from 13.4
.ug/ml X 10-4 to 10-7, as compared with the absence of the
antibody (P < 0.001). The peak enhancement index was 1.41 at
dilution l0-7. In contrast, N70-l.5e failed to exhibit enhance-
ment of infection even at concentrations as low as 730 ,ug/ml
X 10-I Instead, infection was significantly reduced by the pres-
ence of monoclonal antibody N70-1.5e at 730 ,ug/ml X 10-'
through lo-', as compared with the absence of IgG (P < 0.05).
These findings indicate that these enhancing and neutralizing
antibodies are different populations ofantibodies, and that this
potent neutralizing antibody does not mediate infection en-
hancement. We also performed an infection enhancement as-
say with the MN strain of HIV-1, and an enhanced level of
infection mediated by N70-2.3a was observed similar to the
results with the IIIB strain (Fig. 2 c), suggesting that the enhanc-
ing epitope detected by N70-2.3a is conserved on IIIB and MN.
The neutralizing HMAb N70 1.5e neutralized MN, but at
higher concentrations than were required to neutralize IIIB
(Fig. 2 d). It did not, however, enhance infection of either the
IIIB or the MN strains.
Distinct epitopes on gpJ20 detected by the neutralizing
HMAb and the enhancing HMAb. These two HMAbs both
belong to the same subclass, IgGl, which can bind to FcR I, II,
and III when forming immune complexes; therefore, their dif-
ferent characteristics must depend on the specific interaction of
the paratopes of the antibodies with determinants on the virus.
The enhancing antibody N70-2.3a must react with a different
epitope ofgp 120 than that which reacts with N70-1.5e. Results
of ELISA showed that HMAb N70-1.5e recognizes a confor-
mational epitope on gp 120 and its binding to gp 120 is inhibited
by rCD4, as previously reported by Ho et al. (12), while HMAb
N70-2.3a does not (data not shown). Also, as shown in Table II,
a competition radioimmunoassay demonstrated that the bind-
ing of radioiodinated HMAb N70-2.3a was inhibited by unla-
beled N70-2.3a, but not by N70-1.5e. These data indicate that
the two antibodies bind to distinct epitopes.
Effect ofthe enhancingHMAb combined with the neutraliz-
ing HMAb. We examined the effect of mixing the enhancing
HMAb and the neutralizing HMAb together on enhancement
of infection to correspond to an in vivo situation (Fig. 3). HIV-
1 infection was significantly enhanced by the presence ofmono-
clonal antibody N70-2.3a at 17.5 ,ug/ml X 10-6 (the enhance-
ment index was 1.49), as compared with the absence of the
antibody (P < 0.01). On the other hand, infection was signifi-
cantly reduced by the addition of the same amount of the
monoclonal antibody N70-1.5e to the monoclonal antibody
N70-2.3a, resulting in neutralization at dilution 1O' (P <0.01)
and inhibition of enhancement at dilution 10-6.
Identification of the epitope recognized by the enhancing
HMAb. We used recombinant HIV-1 gpl20 polypeptides in
ELISA (15) to localize the epitope for the enhancing HMAb
N70-2.3a because this antibody failed to bind to gpl20 under
reducing conditions (data not presented). As shown in Fig. 4,
N70-2.3a binds to full-length env 2-3 (denatured, nonglycosy-
lated gp120) but not to the amino-terminal halfofgpl 20 env 1.
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Figure 2. HIV-1 infection enhancement activities of human mono-
clonal antibodies N70-2.3a (a) and N70-1.5e (b). Infection enhance-
ment assays were performed with HTLV-IIIB and U937 cells as de-
scribed in Methods. The protein A column-purified IgG monoclonal
antibodies were serially diluted in phosphate-buffered saline at 10-'
through 10-'. A diluted sample (900 Ml) was mixed with an HIV-1
inoculum (100 Ml, 5 x 103 TCID50) and incubated for 30 min at 4°C.
A half million U937 cells were incubated with these mixtures,
washed, and then incubated as described above. Culture supernatants
were harvested on day 5 for determination ofp24 content. The con-
centrations of the monoclonal antibodies were measured by nephe-
lometry by the use of antibodies to IgG Fc (Beckman Instruments,
Inc., Brea, CA). Sample antibodies N70-2.3a and N70-l.5e contain
13.4 and 730.0 ug/ml, respectively. Shown is a representative experi-
ment of three performed. Results are expressed as the mean±SD of
duplicate cultures. HIV-l infection enhancement activities ofhuman
monoclonal antibodies N70-2.3a (c) and N70-1.5e (d) with a HIV
strain MN. Infection enhancement assays were performed with
HTLV-IIIMN and U937 cells as described above.
The antibody is also reactive with the carboxyl-terminal halfof
gpl20 env 4 or env 4D3, irrespective of V3 region. As the
antibody also binds to env 2-3D3 as well as env 2-3D (16), the
Table II. Competition Radioimmunoassay ofHuman Monoclonal
Antibodies (HMAbs) to HIV-J gpJ20
HIV-1 Unlabeled 125I-labeled
glycoprotein HMAb HMAb Counts bound
cpm
+ N70-2.3a 3330
+ N70-1.5e N70-2.3a 3060
+ N70-2.3a N70-2.3a 1133
N70-2.3a 920
epitope for the enhancing antibody N70-2.3a is located within
the conserved sequences between amino acid residues 272 and
509 of gp120. Similar results were obtained using a spot blot
procedure (data not shown).
Comparable affinity ofHMAbs. As shown in Fig. 5, binding
of N70-2.3a to solid phase gp120 was almost completely
blocked at all concentrations ofrgp 120, while no concentration
of rgp120 used was able to block binding of N70-1.5e. These
data therefore indicate that the relative affinity of N70-1.5e is
low in comparison with the affinity of N70-2.3a.
Discussion
Antibody-dependent enhancement of HIV- 1 infection is me-
diated by complement receptors (1) or by FcRs for IgG (3). A
previous study has shown that an enhancing epitope that medi-
ates complement receptor-dependent enhancement of infec-
tion is present at AA586-620 within gp4l ofHIV-1 (19). How-
ever, the epitope(s) that induce antibodies mediating FcR-de-
pendent enhancement of HIV- 1 infection have not been
defined, and it is not known if enhancing epitopes are located
on gp 120. Furthermore, a major question concerning whether
enhancing antibodies and neutralizing antibodies can be distin-
guished has not been previously addressed.
In the present study, we attempted to characterize enhanc-
ing antibodies involved in FcR-mediated enhancement of
HIV- 1 infection by using human monoclonal antibodies reac-
tive against the gp 120 of HIV- 1. The results indicate that en-
hancing and neutralizing antibodies can be induced by differ-
ent epitopes on gp120.
The relative concentrations ofantibody molecules and viri-
ons required to demonstrate neutralization by HMAb N70-
1.5e and enhancement by N70-2.3a raises some questions. En-
hancement of HIV-l infection by the antibody N70-2.3a oc-
curs at very low concentrations of antibody, or in antigen
excess when the number of virions may be greater than the
30 Figure 3. Effect of mix-
ing enhancing mono-
25- clonal antibody N70-
2.3a and neutralizing
20- / monoclonal antibody
J/ N70-1.5e on infection
t15-$_ / o1,~~enhancement. Assays
were performed with
cL X y o/HTLVIIIB and U937
10- / cells as described in
\\ // Methods. The protein A
5 - column-purified IgG
monoclonal antibodies
o were used. The concen-
HIV 10-' 104 trations ofthe antibod-
Aione x 17.5 ig/ml ies were measured by
nephelometry. Enhanc-
ing monoclonal antibody N70-2.3a (17.5 Mg/ml) alone (o) or a mix-
ture of the antibody N70-2.3a (17.5 ,ug/ml) and the same amount of
neutralizing antibody N70-1.5e (17.5 Mg/ml) (.) were diluted in
phosphate-buffered saline at 10-1 and 10-6, respectively. A diluted
sample (0.9 ml) was mixed with an HIV-l inoculum (0.1 ml, 5 X 103
TCIDO), and incubated for 30 min at 40C. A halfmillion U937 cells
were infected with these mixtures as described above. Culture super-
natants were harvested on day 5 for determination of p24 content.
Results are expressed as the mean±SD of duplicate cultures.
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Figure 4. Reactivity of HMAb N70-2.3a to various envelope poly-
peptides. Nonglycosylated. HIV-l (SF2) recombinant gpl20 polypep-
tides which are illustrated on the bottom were used. Schematic dia-
gram of the HIV- envelope gene showing locations of hypervariable
regions and variants produced in yeast. Constant domains are shown
in white and variable sequences in black. SS, signal sequence; TM,
transmembrane domain. The bars shown below the diagram delineate
the regions that were expressed in variants of gpl2O in yeast, and
deleted regions are shown with thin connecting lines. Deletion vari-
ants were named to correspond with the variable regions deleted.
Polypeptides were absorbed onto microtiter plates. Biotinylated
HMAb N70-2.3a which was diluted serially was added and detected
by ELISA. The optic density represents the relative amounts of
HMAb N70-2.3a bound to polypeptides.
number ofantibody molecules. On the other hand, for neutral-
izing antibody N70-1.5e we find that neutralization requires
much higher concentrations ofantibody (antibody excess). The
quantitation of HIV- 1 may vary in different HIV- 1 pools. We
did, however, obtain similar results in repeated experiments
N70-2.3a N70-1 .5e
.it-so .5-
4 2 1 .5 .25 o 4 2 1 .5 .25 0
Concentration of gpl20 (Ig/ml)
Figure 5. Comparison
of relative affinities of
HMAbs 2.3a and 1.5e
to gpl20. Assays are
performed as described
in Methods. Results are
expressed as means of
triplicate determination;
error bars indicate stan-
dard deviations.
which indicates that large differences in virus-antibody ratios
are required for neutralizing versus enhancing activity of these
monoclonal antibodies to be detected. It is of interest that anti-
body N70-1.5e did not enhance infection even at higher ratios
of virus to antibody. The neutralizing antibody N70-l.5e,
which has the same Fc portion as antibody N70-2.3a, may also
help the virus bind to the cell surface via its attachment with
FcRs similar to enhancing antibodies. We presume, therefore,
that this antibody may inhibit HIV- I infection at a level of the
infection process by blocking a site on gpl20 involved in CD4
binding (12). We have recently found convincing evidence that
the CD4 molecule is required for FcR-mediated enhancement
of HIV- I infection (20), in agreement with the results of Perno
et al. (21). It is also of interest that the relative affinity of N70-
2.3a is higher than that of N70-l.5e. This may be the reason
that very low concentrations of enhancing antibody N70-2.3a
can bind virions efficiently.
We analyzed the effect of mixing the enhancing HMAb and
the neutralizing HMAb together on enhancement of infection
to correspond to an in vivo situation. Since these HMAbs N70-
1.5e and N70-2.3a were produced by B cell lines derived from
an HIV- 1-infected individual, they are likely to represent anti-
bodies existing in the serum. Infection was significantly re-
duced by the addition of the same amount of the monoclonal
antibody N70-1.5e to the monoclonal antibody N70-2.3a, re-
sulting in inhibition of enhancement. These limited results
need to be extended, but they may explain why the activity of
HIV- 1-enhancing antibodies in human sera is detected when
the neutralizing antibodies are diluted out. Probably in sera
certain concentrations of neutralizing antibodies inhibit en-
hancement by enhancing antibodies; however, after dilution of
low concentrations of neutralizing antibodies enhancing activ-
ity can be detected. This result also appears to be consistent
with our interpretation of the differential functions of the two
monoclonal antibodies stated above. Although the number of
the virions which bind to and/or internalize into the cell may
be increased by mediation of antibody-FcR interactions, this
increased entry of virions into cells may be abrogated by the
effect of the neutralizing HMAb N70-l.5e. In sera, if neutraliz-
ing antibodies are dominant over the enhancing antibodies, we
would not see enhancing activity. Thus, we tested the serum
from the same donor from whom HMAb N70-1.5e and N70-
2.3a were derived, and found no enhancing activity in it. How-
ever, the fact that enhancement can be detected in many sera at
subneutralizing concentrations indicates that neutralizing anti-
bodies, such as HMAb N70-1.5e, may be present in lesser con-
centrations in vivo. Perhaps the number ofenhancing epitopes
on gp 120 is higher than neutralizing epitopes. HMAbs will pro-
vide invaluable tools for further study to characterize epitopes
that elicit neutralizing or enhancing antibodies in infected hu-
mans.
These results have implications for the potential develop-
ment ofsafe HIV vaccines that will induce neutralizing and not
infection-enhancing antibodies. The mapping study ofthe epi-
tope which is recognized by the enhancing antibody N70-2.3a
indicates that the antibody binds to a conformational epitope
on nonvariable sequences in the carboxyl-half(AA272-509) of
gp 120. This suggests that such an enhancing antibody may be
induced by various strains of HIV-l and may be present in
many HIV- 1-infected individuals. Extensive studies to define
precisely the domains that elicit enhancing antibodies is desir-
able for the future design of anti-HIV vaccines.
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